A New Way To Tackle Deal Valuations: Infectious Disease As A Case Study
Executive Summary
Despite regulatory uncertainty, the growing problem of antibiotic resistance – especially for gram-negative organisms – has forced big drug companies to take renewed interest in novel anti-infectives.
You may also be interested in...
Rib-X Teams With Sanofi To Develop Novel, Broad-Spectrum Antibiotics
Deal enables biotech to monetize a portion of its ribosome research while maintaining control over larger segments.
Deals In Depth: February 2020
Sangamo licensed Biogen zinc finger protein transcription factor candidates in an alliance worth over $2bn. Exercising an option it gained in 2017, Takeda bought celiac disease-focused PvP Biologics for up to $330m in earn-outs. A strong showing of IPOs prompted biopharma financing to increase from last month.
Deals Shaping The Medical Industry, March 2020
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2020.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: